Category Archives: GENZ

Illumina Shines After Appearing on Watch List

In yesterday’s note, we outlined what appears to be the conclusion of Sanofi-Aventis’ (SNY) attempt to buy Genzyme (GENZ) in a $20 billion deal that was 7 months in the making. Genzyme was on our October 30, 2009 Nasdaq 100 Watch List before Sanofi-Aventis made the initial offered to buy Genzyme (GENZ) in July of 2010. At the time, the New Low team suggested that because so many of the companies on our Nasdaq 100 Watch List were in the drug sector, there was likely to be acquisitions or merger in the same industry. The alternative reaction is for individual investors to bid the price of the stocks higher.

On our December 19, 2009 Nasdaq 100 Watch List, Genzyme (GENZ) shared a place on the list with Illumina (ILMN) (article here). As mentioned yesterday, the price performance of Illumina (ILMN) since being on our December 19, 2009 Watch List has been amazing. Below is a comparison chart of Illumina (ILMN) and Genzyme (GENZ).



Illumina (ILMN) has managed to increase in value by over 3 times as much as Genzyme in the same period. Even the sweetened offer by Sanofi-Aventis, from $69 a share to $74, is not enough to put a dent in the gap between Illumina’s performance against Genzyme. In mid-January 2010 (article here), we pointed out the strength of Illumina’s reported earnings which pushed up the share of the company 15% in a single day. Purchase of ILMN in mid-January 2010 have overshadowed the rise of Genzyme in its path to acquisition.

For companies that appear on our Dividend or Nasdaq 100 lists, we believe it is only a matter of time before the market recognizes the value. In many instances, even a cursory overview of the company’s financial information using sources like Value Line, Morningstar and Mergent (assuming the worst case scenario) can provide a fair approximation of true worth.

Please revisit New Low Observer for edits and revisions to this post. Email us.

New Low Team Nails it on Genzyme Deal

It appears that the long predicted outcome for Genzyme (GENZ) is about to come to fruition.  In our October 30, 2009 Nasdaq 100 watch list (article here), we suggested that because of the concentration of drug companies at or near a new low, the prospects were good that an acquisition had to take place in the industry. 
We had already highlighted the individual prospects of Genzyme on October 17, 2009 (article here).  In that piece, we said:
"Finally we have Genzyme Corp. (GENZ) at $55.94. This stock has historically traded at 19 times cashflow. The 2008 cashflow for this GENZ was $2.82, according to Mergent’s (Valueline had the higher figure.) GENZ, although selling 19% above the 52-week low, is a far superior value proposition. The shares outstanding have grown by 2.7% from 2006 to 2008 while the long-term debt has fallen by 85% over the same time frame."
Apparently, it took Sanofi-Aventis nearly 9 months to realize the Genzyme was as good as we believed it to be.  Sanofi-Aventis offered $69 in July of 2010 but Genzyme's natural reaction was to say, "pay or don't play."  Sanofi-Aventis caved and offered $74 to close the deal. 
In a fashion similar to a ratings agency, Moody's decided to suggest that it may raise the credit rating of Genzyme.  Duh!  The company is about to ink a $20 billion takeover offer.  This raises the prospect that another company will step in and make a counter offer for Genzyme.  This could lead to a true bidding war thereby nullifying the need for credit ratings for the purposes of borrowing money. 

We hope that the work we have done on this site is evidence of the soundness of our strategy.  Tomorrow we will outline another stock from our Nasdaq 100 Watch List that has made the Genzyme deal look like peanuts in comparison.

Please revisit New Low Observer for edits and revisions to this post. Email us.

Flash Crash Follies

Flash Crash Follies is a running tally of stocks that get ensnared by regulations as an outgrowth of the May 6, 2010 "flash crash."  While the explosive crash of stocks (either up or down) on the NYSE is a symptom to a bigger problem, we want to chronicle what was never reported to have happened before May 6, 2010.  Action packed moves in the price of stocks that will bring pleasure, pain and finally resignation at the state of the free market as we know it. 
We've added commentary from the mouthpiece of the NYSE or NASDAQ to explain away "erroneous" trades or canceled orders.  Before long we're going to hear politicians getting into the fray on specific "erroneous" trades.  What will this devolve into nobody knows for sure.  However, we're willing to bet that in due time, the treatment of the symptom will become a distinct problem of its own.

"...the folly of human laws too often encumbers its operations." Adam Smith

September 28, 2010 (date contains Bloomberg screen shots from third party source)
Apple (AAPL), Research In Motion (RIMM), IBM (IBM), Dell (DELL), General Electric (GE), Oracle (ORCL), Microsoft (MSFT), Hewlett-Packard (HPQ)
Stocks of the above noted companies took a dive at the same time on September 28, 2010.  The exchanges didn't provide commentary on the actions taken as a result of the instantaneous decline and rise in value.  many have attributed specific declines to "newsworthy" issues related to the specific companies.  However, no one has stepped forward to explain the statistical anomally of so many companies experiencing the same issue at exactly the same time.

July 29, 2010 (date contains article link from third party source)
Cisco Corp. (CSCO)
At 10:41am EST, Cisco (CSCO) shares spiked by 11% due to an order imbalanced triggered by 100 shares.  CSCO rose from $23.37 to $26 which triggered circuit breakers prompting Jamie Selway, managing director at broker White Cap Trading LLC in New York, “We’re stopping trading in incomparably liquid products because of dumb mistakes...”  In this instance, the NYSE-owned AMEX which handles very few trades in CSCO could not fulfill orders placed on their exchange even through there were plenty of shares being trades on alternative exchanges.  Ultimately, CSCO was trading with the liquidity of a penny stock.  Soon enough, firms with intimate knowledge of where they place their trade can play the illiquidity to their advantage.  The AMEX and other small exchanges will be under attack.

July 23, 2010 (date contains article link from third party source)
Genzyme Corp. (GENZ)
At 1:18pm EST and 1:25pm EST, Genzyme Corp. (GENZ) triggered circuit breakers when the stock attempted to rise by more than 10% on two separate occasions within the same day due to rumors about a takeover. Nasdaq OMX spokesman Robert Madden gave no justification for the halt in trading. However, traders and money managers expressed the sentiment that “at some point, you need to let efficient market theory rule how stocks trade.” In this case, Genzyme wasn't allowed to rise as much as speculators were willing to bid the price up.

July 6, 2010 (date contains article link from third party source)
Anadarko Petroleum (APC)
At 10:56am EDT to 11:01am EDT, Anadarko shares trade from $39.14 to $99,999.99. “‘We are still learning from the experience,’ he [Ray Pellechia] said.”
June 29, 2010  (date contains article link from third party source)
Citigroup (C)
At 1:03pm EDT, Citigroup shares trade from $3.80 to $3.3174 or down 12.7%. “The erroneous trade was subsequently canceled, NYSE spokesman Ray Pellechia said.”

June 16, 2010 (date contains article link from third party source)
Washington Post (WPO)
At 3:07pm EDT Washington Post stock trades from $450 to $919 or up 104%. All trades were cancelled. “‘What happened today was not due to a substantive, true move in the stock. It was simply an error,’ NYSE spokesman Ray Pellechia said.”
 
Email our team here.

Nasdaq 100 Watch List

Watch List Summary

At the end of the week for September 17, 2010, the top performing stocks from our Nasdaq 100 list for August 15, 2010 are Oracle (ORCL) with a gain of 21.27%, Qualcomm (QCOM) with a gain of 12.07% and Computer Associates (CA) with a gain of 11.57%.
The worst performing stocks from our August 15th watch list are Intel (INTC) down –1.78%, Applied Materials (AMAT) down –1.34% and Activision (ATVI) down –0.46%.
The average gain for the watch list was 6.33%. Of the two stocks that we pointed out as being standouts from August 15th, Garmin (GRMN) exceeded the average return by climbing 9.57% while Paychex (PAYX) underperformed the average gain by rising 3.92%.
A distinction that needs to be made between this week’s list and our August 15th list is that we’ve ranking the companies on this list by those stocks nearest their 52-week low. Our previous list was ranked by those stocks that had the highest dividend yield and within 20% of their respective 52-week low.

Performance Review

The following is a total return (appreciation plus dividends) performance review of our Nasdaq 100 Watch List from September 11, 2009:
  • Stericycle (SRCL) up 44.48%
  • Genzyme (GENZ) up 25.54%
  • Pharmaceutical Product Development (PPDI) up 20%
  • Cephalon (CEPH) up 5.92%
As a group, the average gain for the stocks mentioned was 23.99%. This is contrasted by the Nasdaq 100 gain of 16.07% in the same period of time.

*chart does not reflect dividend reinvestment for PPDI


Nasdaq 100 Watch List

Below are the Nasdaq 100 companies that are within 20% of their respective 52-week lows. Stocks that appear on our watch lists are not recommendations to buy. Instead, they are the starting point for doing your research and determining the best company to buy. Ideally, a stock that is purchased from this list is done after a considerable decline in the price and rigorous due diligence.

Symbol Name Price P/E EPS Yield P/B % from Low
PAYX Paychex, Inc. 25.95 19.67 1.32 4.80% 6.67 5.27%
INTC Intel Corporation 18.81 11.26 1.67 3.40% 2.3 6.87%
AMAT Applied Materials, Inc. 11.02 24.44 0.45 2.50% 2.03 7.33%
YHOO Yahoo! Inc. 13.89 22.77 0.61 N/A 1.59 7.34%
MXIM Maxim Integrated Products, Inc. 16.91 41.86 0.4 5.00% 2.15 7.91%
GILD Gilead Sciences, Inc. 34.56 10.47 3.3 N/A 4.58 8.93%
ATVI Activision Blizzard, Inc 10.82 41.94 0.26 1.30% 1.21 8.96%
DELL Dell Inc. 12.45 15.74 0.79 N/A 3.92 9.80%
RIMM Research In Motion Limited 46.72 10.24 4.56 N/A 3.2 9.85%
AMGN Amgen Inc. 55.22 11.73 4.71 N/A 2.28 9.87%
DISH DISH Network Corporation 18.77 11.26 1.67 N/A N/A 10.02%
CSCO Cisco Systems, Inc. 21.86 16.46 1.33 N/A 2.82 10.31%
XRAY DENTSPLY International Inc. 30.66 16.55 1.85 0.70% 2.6 10.45%
MSFT Microsoft Corporation 25.22 12 2.1 2.10% 4.76 10.95%
SPLS Staples, Inc. 19.49 17.26 1.13 1.80% 2.2 11.69%
PDCO Patterson Companies Inc. 27.15 14.67 1.85 1.50% 2.3 12.52%
SHLD Sears Holdings Corporation 66.83 27.38 2.44 N/A 0.9 12.87%
GOOG Google Inc. 490.15 21.29 23.03 N/A 3.77 13.03%
LIFE Life Technologies Corporation 46.51 29.91 1.56 N/A 1.97 13.16%
STX Seagate Technology. 11.16 3.55 3.14 N/A 1.95 13.41%
FLIR FLIR Systems, Inc. 27.24 18.52 1.47 N/A 3.25 13.50%
GRMN Garmin Ltd. 29.64 8.95 3.31 5.10% 2.21 13.52%
TEVA Teva Pharmaceutical Industries 53.48 19 2.82 1.20% 2.48 13.81%
FLEX Flextronics International Ltd. 5.55 15.72 0.35 N/A 2.26 14.20%
COST Costco Wholesale Corporation 61.29 21.93 2.8 1.30% 2.43 14.75%
HSIC Henry Schein, Inc. 56.35 15.82 3.56 N/A 2.31 14.77%
CERN Cerner Corporation 79.18 31.31 2.53 N/A 3.83 14.85%
CELG Celgene Corporation 55.25 29.99 1.84 N/A 5.11 15.06%
CA CA Inc. 20.44 13.43 1.52 0.80% 2.02 15.48%
ERTS Electronic Arts Inc. 16.26 N/A -1.06 N/A 1.96 15.63%
VRTX Vertex Pharmaceuticals Incorpor 36.25 N/A -3.53 N/A 9.01 16.00%
KLAC KLA-Tencor Corporation 31.05 25.31 1.23 3.30% 2.32 16.34%
STLD Steel Dynamics, Inc. 15.01 15.73 0.95 2.00% 1.58 16.45%
WCRX Warner Chilcott plc 22.75 11.2 2.03 N/A 2.82 16.55%
LOGI Logitech International S.A. 15.39 22.57 0.68 N/A 2.68 16.86%
CEPH Cephalon, Inc. 62.26 12.48 4.99 N/A 2.09 17.36%
URBN Urban Outfitters, Inc. 34.11 22.19 1.54 N/A 4.26 18.85%
FWLT Foster Wheeler AG. 24.19 10.8 2.24 N/A 3.46 18.99%
FISV Fiserv, Inc. 53.56 17.16 3.12 N/A 2.57 19.55%
JBHT J.B. Hunt Transport Services, I 35.26 26.73 1.32 1.40% 7.56 19.73%
CTAS Cintas Corporation 27.71 19.64 1.41 1.70% 1.67 19.96%

Genzyme Corp: Value is Finally Being Recognized

There has been a lot of news about Genzyme (GENZ) being considered as a takeover candidate by Sanofi-Aventis (SNY). Typically, rumors are simply that, nothing more than prattle about a washed up company that has little or no life remaining. However, we have demonstrated that discussions of Genzyme (GENZ) being taken over are not so far fetched.
On October 17, 2009 (article link), we had only four companies that were on our Nasdaq 100 Watch List that was within 20% of their respective 52-week lows. This was in contravention to the overall market; which was racing higher every day. So compelling were the companies on the list that we felt it was necessary to give mini-profiles on their value propositions.
Genzyme (GENZ) was one such company that was on that list. We included Genzyme (GENZ) as the last company we profiled since we felt that it was “…a far superior value proposition.” This was despite the fact that Genzyme (GENZ) was the farthest from the new low among the companies on the list.
On October 30, 2009 (article link), we weren’t surprised that drug and medical device makers dominated our list of companies near a new low. In that posting to our site we said, “The continued undervaluation of these companies makes them prime targets for acquisition…” Genzyme (GENZ) was on the list and trading at $50.60. The performance of the stocks that were on the on the October 30 watch list is as follows:

The average gain for the group was 15.32% in 9 months. The worst performing stock has been Gilead Sciences (GILD) with a decline of 22.21%. The best performing stock has been Biogen (BIIB). Our sanguine view on Gilead Sciences (GILD) may be worth reviewing since it has fallen so much since October 30, 2009.
Genzyme has already indicated that they’re not going to accept the Sanofi-Aventis (SNY). This opens the door for competing bids, which should push the price up. Our view at this time is that Genzyme is strictly a speculation, at best, given the rise of nearly 33% since our mention of being a takeover candidate in October 2009.

Odds and Ends

Question:
Do you think Richard Russell has been overrated regarding his abilities to forecast the directions of the markets? It seems like one good call (1975) allows one in his position to reap benefits for years despite demonstrating no skill when one goes back and, with the benefit of hindsight, takes a critical look at the entire record.
Our Thoughts:
Anyone, including NLO team, who attempts to predict the stock market is under extraordinary pressure. The challenge that Russell presents is that he often ignores that he has a bias towards the market falling rather than rising. This becomes a problem when, against his experience and better judgment, Dow Theory might be indicating that the direction is up despite all the negative market fundamentals.
Again, Dow Theory is supposed to include all the current and foreseeable hopes and fears as it relates money. I think that if Russell would follow Dow Theory or even his PTI indicator more often he would get a more accurate readings on the market.
It should be noted that within the content of his Dow Theory Letters from 1958 to the present, there are many great calls.  As I post more reviews of Russell’s letters, I will be able to point out too many instances of where Russell was spot on.
Unfortunately, Russell often didn’t stick to his guns or he forgot his earlier good advice or information. As an example, Russell talks about the importance of compounding. This cannot be accomplished if you’re buying and selling based on Dow Theory. Another example is Russell’s commentary on values. You can’t speak of values if you’re primarily focused on ETFs, index funds or stocks that don’t increase their dividends when plenty of them exist.
The pace and excitement of the markets become challenging for anyone to remain focused on the fundamentals. Russell has fallen astray of the basic principals of Dow Theory and value investing. Although the two seem mutually incompatible, there is a middle ground which Russell hasn’t attempted to address in all the years of his work.
Question:
I'm curious that you write "In my observations, market volume has increasingly become an addendum to Dow Theory." Meaning, only as a sidelight, or as an increasingly important variable? It does seem harder to judge given increased manipulation on light volume. Looks like lots of stick saves last week.
Answer:
It may be a function of the markets being driven by various large institutions (mutual funds, hedge funds, index funds, ETFs etc...) but volume seems to be less reliable when trying to determine sentiment and trends on the NYSE. I suspect that the diminished impact of smaller participants and derivative markets have had a lot to do with my concerns about volume not being a strong indicator. However, I will continue track volume just in case.
Question:
What did you do with the proceeds from the sale of WTR?
Answer:
After investing in WTR we recommended CEPH and SVU which generated 13% and 11% gains respectively. Both stocks were on our Watch Lists and in each case we accomplished our targets and made subsequent sell recommendations. In addition to our posted recommendations, we also participated in CWT and GENZ. Both positions accomplished our short-term after tax goals which allowed for the purchases of new stocks on our dividend Watch List.
Our article titled “Meridian Biosciences and Other Profitable Market Lessons” provides a framework for the strategy we’d like to employ when investing in Dividend Achievers. Another article that weighs heavily on our investment decisions is titled “It Isn’t Easy Being Green.” That article outlined Hetty Green’s approach to handling her funds when not invested in stocks. We’ve simply applied a similar strategy to Dividend Achievers and Nasdaq 100 stocks at a new low (after careful analysis).
Question:
Would you venture to provide a top pick from your current dividend achievers list?
Answer:
As you can tell, the current list has too many companies that are candidates for investment. Without providing any detailed analysis,  I would say that my top four choices for additional research would be Ritchie Bros Auctioneers (RBA), Northern Trust (NTRS), Dentsply (XRAY), and Meridian Biosciences (VIVO).  We expect, and hope, that the price of these stocks will fall further while we get more research in.  We're using the March 2009 low as our benchmark for all investment analysis going forward and we hope that you do the same.
Russell Blurb:
For what it is worth Richard Russell’s commentary today (July 12, 2010) seems to fly in the face of the commentary that he gave on Friday July 9, 2010. Go figure:

“The recent non-confirmation by the Transports may have served as an entry spot for bold speculators, but I doubt if the 2007 highs in the Averages will be approached or bettered. Nevertheless, we may see a brief period of better markets, a "breather" in the long life of the bear. I believe this primary bear market will extend into 2016.

A near-term marker or target is to see whether the Dow and the Transports can better their recent June highs. Those highs were 10450.64 for Industrials and 4467.25 for Transports. Write those figures down. I'm betting that the two D-J Averages will not be able to better the June highs. Let's wait and see.”

All I can say is, at least he indicated an upside target that matches the one we came up with yesterday.  Can't understand how he was so bullish on Friday and is now sounding so skeptical today.

Email our team here.

Nasdaq 100 Watch List

Below are the Nasdaq 100 companies that are within 20% of their respective 52-week low.  Stocks that appear on our watch lists are not recommendations to buy.  Instead, they are the starting point for doing your research and determining the best company to buy.  Ideally, a stock that is purchased from this list is done after a considerable decline in the price and considerable due diligence.

Name Price P/E EPS Yield P/B Pct from Yr Low
Gilead Sciences, Inc. (GILD) $38.37 12.31 3.12 0.00% 4.71 0.95%
Apollo Group, Inc. (APOL) $54.41 13.61 4.00 0.00% 6.23 3.07%
QUALCOMM (QCOM) $36.50 19.47 1.88 2.10% 2.90 3.60%
Ryanair Holdings plc (RYAAY) $24.60 0.00 0.00 0.00% 0.00 3.89%
Activision (ATVI) $10.56 124.24 0.09 1.40% 1.22 6.34%
Yahoo! Inc. (YHOO) $15.29 27.40 0.56 0.00% 1.81 9.45%
Genzyme (GENZ) $51.77 125.66 0.41 0.00% 1.84 9.94%
Symantec  (SYMC) $15.62 40.57 0.39 0.00% 3.02 11.82%
Electronic Arts (ERTS) $17.63 0.00 0.00 0.00% 2.29 12.29%
Cephalon, Inc. (CEPH) $59.38 11.84 5.01 0.00% 1.90 13.00%
Logitech (LOGI) $14.63 40.41 0.36 0.00% 2.65 14.03%
Staples (SPLS) $21.66 21.17 1.02 1.60% 2.35 15.71%
Amgen Inc. (AMGN) $54.46 11.56 4.71 0.00% 2.37 17.22%
RIMM (RIMM) $64.92 0.00 0.00 0.00% 0.00 19.56%
Cintas (CTAS) $25.54 23.87 1.07 1.80% 1.61 19.91%

Watch List Summary

The stock that fell the most from last week's watch list was Ryanair Holdings (RYAAY) which fell -14.47% for the week. There were no stocks that had a gain from the previous week, however Genzyme (GENZ) lost the least at -2.80%. 

Company Change from Last Week
Gilead Sciences, Inc. (GILD) -3.49%
Apollo Group, Inc. (APOL) -5.51%
QUALCOMM (QCOM) -5.97%
Ryanair Holdings plc (RYAAY) -14.47%
Activision (ATVI) -4.92%
Yahoo! Inc. (YHOO) -8.11%
Genzyme (GENZ) -2.80%
Symantec (SYMC) -7.36%

In all, the Nasdaq 100 Watch List of last week lost -6.58% as compared to the Nasdaq 100 index which lost a total of -7.56%.  As with our Dividend Achiever Watch List, the smaller losses and larger gains make the Watch Lists a good place to start investigating your next investment opportunities.  Naturally, we expect that all investment decisions should be done with an eye for selectivity and a willingness to harbor a lot of patience.

New on our Nasdaq Watch List this week is Cintas (CTAS) which is also a Dividend Achiever.  Cintas (CTAS) will be closely followed in the days to come since the company has increased its dividend every year for 27 years in a row.  One caveat regarding the CTAS dividend is that it appears to be paid only once a year around the month of February.  This means that poorly timed purchases can result in large losses without being offset by quarterly dividend payments.
Email our team here.

Nasdaq 100 Watch List

Below are the Nasdaq 100 companies that are within 21% of their respective 52-week low. Instead, they are the starting point for doing your research and determining the best company to buy.  Ideally, a stock that is purchased from this list is done after a considerable decline in the price and extensive due diligence.
Symbol Name Price P/E EPS Yield P/B % from low
GILD Gilead 39.71 12.74 3.12 0 4.86 0.40%
APOL Apollo 57.41 14.36 4 0 6.53 8.75%
QCOM QUALCOMM 38.68 20.63 1.88 2.00% 3.09 9.08%
ATVI Activision 11.08 130.35 0.09 1.40% 1.31 11.58%
GENZ Genzyme 53.22 129.17 0.41 0 1.91 13.02%
RYAAY Ryanair 28.16 0 0 0 0 13.46%
YHOO Yahoo! Inc. 16.53 29.62 0.56 0 1.93 18.84%
SYMC Symantec 16.77 43.56 0.39 0 3.13 20.04%
Watch List Summary
The best performing stock from last week's list was Qualcomm (QCOM) which rose 1.12%.  The worst performing stock was Apollo Group (APOL) which declined 9.63%.  Worth noting is the fact that Gilead Sciences (GILD) is moving very close to the October 10, 2008 adjust low price of $37.47.  If GILD falls below the $37 level then the next support level is $27 according to Dow Theory.
This is the first time that Yahoo! (YHOO) has appeared on our watchlist.  However, the most accurate low price should be the $8.95 low price that was attained in November 2008.  I would not be surprised to see YHOO become the subject of a takeover if the price falls any further.
While YHOO's price has gone relatively nowhere in the last year, potential acquirers have an expensive stock price on their hands.  This explains why Hewlett-Packard (HPQ) is buying Palm (PALM).  From the period of one year ago, HPQ's stock price has risen over 40% while PALM's had fallen by over 60% in the same time frame.  Stock prices are getting expensive and the only way to resolve this is by issuing more shares to raise capital or by acquiring another company.

Nasdaq 100 Watch List

Below are the Nasdaq 100 companies that are within 21% of the 52-week low.

Symbol Name Price P/E EPS Yield P/B % from Low
GILD Gilead Sciences 41.67 14.77 2.82 0 5.74 4.44%
QCOM QUALCOMM 38.25 30.7 1.25 1.90% 3.08 7.87%
GENZ Genzyme Corporation 53.93 35 1.54 0 1.85 14.53%
ATVI Activision Blizzard 11.6 136.47 0.09 1.30% 1.35 16.82%
RYAAY Ryanair Holdings 29.19 N/A - 0 0 17.61%
APOL Apollo Group, Inc. 63.53 15.89 4 0 7.34 20.34%

This list is strictly for the purpose of researching whether or not the companies have viable business models or are about to go out of business. These companies are deemed highly speculative unless otherwise noted.

Email our team here.

Nasdaq 100 Watch List

Below are the Nasdaq 100 companies that are within 20% of the 52-week low. Instead, they are the starting point for doing your research and determining the best company to buy.  Ideally, a stock that is purchased from this list is done after a considerable decline in the price and extensive due diligence.

Symbol Name Price P/E EPS Yield P/B % from Low
GILD Gilead 45.7 16.19 2.82 0 6.4 10.63%
GENZ Genzyme 53.64 34.81 1.54 0 1.82 13.91%
RYAAY Ryanair 29.23 0 0 0 0 17.77%
ATVI Activision 11.79 138.71 0.09 1.30% 1.36 19.33%
SYMC Symantec 16.68 43.32 0.39 0 3.1 19.40%

This list is strictly for the purpose of researching whether or not the companies have viable business models or are about to go out of business. These companies are deemed highly speculative unless otherwise noted.

Email our team here.

Nasdaq 100 Watch List

Below are the Nasdaq 100 companies that are within 20% of the 52-week low. Instead, they are the starting point for doing your research and determining the best company to buy.  Ideally, a stock that is purchased from this list is done after a considerable decline in the price and extensive due diligence.

Symbol Name Trade P/E EPS (ttm) Yield P/B % from Low
GILD Gilead 45.7975 16.2 2.822 0 6.48 10.86%
GENZ Genzyme 52.8 34.3 1.54 0 1.81 12.13%
SRCL Stericycle 54.58 27 2.03 0 5.44 18.76%
QCOM QUALCOMM 42.17 33.8 1.25 1.60% 3.32 18.92%
APOL Apollo Group 63.14 15.8 4 0 7.13 19.61%
RYAAY Ryanair 29.75 N/A - 0 N/A 19.86%
This list is strictly for the purpose of researching whether or not the companies have viable business models or are about to go out of business. These companies are deemed highly speculative unless otherwise noted.
Email our team here.

Nasdaq 100 Watch List

Below are the Nasdaq 100 companies that are within 20% of the 52-week low.

Symbol Name Price P/E EPS (ttm) Yield P/B % from Yr Low
GILD Gilead Sciences 45.34 16.1 2.82 0 6.5 9.76%
GENZ Genzyme Corp. 53 34.4 1.54 0 1.8 12.55%
APOL Apollo Group 61.28 14.7 4.16 0 6.7 16.08%
QCOM QUALCOMM 41.83 33.6 1.246 1.60% 3.3 17.96%
FSLR First Solar, Inc. 116.5 15.5 7.53 0 3.6 18.02%
SRCL Stericycle, Inc. 54.5 26.9 2.03 0 5.5 18.58%

This list is strictly for the purpose of researching whether or not the companies have viable business models or are about to go out of business. These companies are deemed highly speculative unless otherwise noted.

Email our team here.

Nasdaq 100 Watch List

Symbol Name Trade P/E EPS Yield P/B Pct from Yr Low
QCOM QUALCOMM 38.95 31.3 1.25 1.70% 3.1 9.84%
ERTS Electronic Arts Inc. 17.77 N/A -2.3 N/A 2.3 13.18%
GILD Gilead Sciences, Inc. 47.42 16.8 2.82 N/A 6.7 14.79%
FSLR First Solar, Inc. 115.5 15.4 7.53 N/A 3.6 17.04%
SRCL Stericycle, Inc. 54.49 26.9 2.03 N/A 5.5 18.56%
APOL Apollo Group, Inc. 63.02 15.2 4.16 N/A 6.8 19.38%
GENZ Genzyme 56.91 36.9 1.54 N/A 2 20.85%

Watch List Summary

This week on the Nasdaq 100 Watch List there were several notable changes. We had Stericycle (SRCL) decline -1.55% for the week. Stericycle (SRCL) had the largest decline of stocks that were on our watch list from the prior week. It appears that SRCL is on its way to declining to the previous low of $50.62. Since May 2009, SRCL has managed to trace out higher lows. SRCL is currently selling 29% below the 10-year average P/E ratio and 24% below the 10-year average price to cash flow ratio. Counteracting those positive features is that the company is selling almost 7% above the 10-year average price to book ratio. According to Morningstar, SRCL is a wide moat company or a company that a significant advantage that is challenging for new competitors to enter the industry (SRCL chart below).

The leading stock on the Nasdaq 100 in the past week has been First Solar (FSLR), which gained 6.37%. FSLR is selling at least 60% below the 3-year average price to book, price to cash, price to earnings, and price to sales. Lacking any 10-year data on First Solar (FSLR) my intuition tells me to consider this stock only in a small portion of the portfolio and that I’m willing to lose 100% of invested funds. FSLR seems like the Whole Foods (WFMI) of the energy sector, great concept but little in the way of sustainability.
Finally, the sector that appears to be on the move is the video game group. Both Electronic Arts (ERTS) and Activision Blizzard (ATVI) gained 3.80% and 3.99% respectively. The move higher was also confirmed by Gamestop Corp (GME), which rose just over 6% for the week.
In a footnote to our Dividend Achiever Watch List, we wish to bring to your attention the recent rumors that SuperValu (SVU) is being considered as a takeover candidate. Since our Investment Observation on January 6, 2010, the stock has run up 33.72%. SuperValu (SVU) sports a price to earnings ratio of 38 and a price to sales ratio that is half of its 5-year average. The price to book ratio is currently at the 5-year average. SVU seems a bit rich for me at this time however the performance of the stock since our January 6th article does not surprise our team.
The Nasdaq 100 Watch List is strictly for the purpose of researching whether or not the companies have viable business models or are about to go out of business. These companies are deemed highly speculative unless otherwise noted.
 -Touc

Email our team here.

Nasdaq 100 Watch List

Below are the Nasdaq 100 companies that are within 21% of the 52-week low. This list is strictly for the purpose of researching whether or not the companies have viable business models or are about to go out of business. These companies are deemed highly speculative unless otherwise noted (view all.)

-Touc

Symbol Name Trade P/E EPS Yield P/B % from Low
Apollo Group
56.92
13.70
4.16
N/A
6.56
7.82%
Electronic Arts
16.75
N/A
-2.31
N/A
2.09
13.56%
First Solar
116.00
15.46
7.50
N/A
4.37
14.97%
Activision
10.79
125.47
0.09
1.39%
1.28
16.65%
Pharma Prod.
21.20
15.81
1.34
2.83%
1.87
17.97%
Stericycle
54.30
26.81
2.03
N/A
5.36
18.15%
Genzyme
55.97
31.91
1.75
N/A
1.94
18.86%
Gilead
48.84
17.31
2.82
N/A
6.84
20.24%

Nasdaq 100 Watch List

Below are the Nasdaq 100 companies that are within 21% of the 52-week low. This list is strictly for the purpose of researching whether or not the companies have viable business models or are about to go out of business. These companies are deemed highly speculative unless otherwise noted.

Symbol Name Trade P/E EPS (ttm) Yield P/B % from Low
Electronic Arts
16.06
N/A
-4.06
N/A
1.97
8.88%
Apollo Grp
59.22
14.25
4.16
N/A
6.23
12.18%
First Solar
115.10
15.34
7.50
N/A
3.94
14.07%
Stericycle
51.36
25.36
2.03
N/A
5.17
15.18%
Gilead Sci.
47.01
16.66
2.82
N/A
6.47
15.73%
Genzyme Corp.
55.73
31.77
1.75
N/A
1.93
18.35%
QUALCOMM
38.84
31.17
1.25
1.80%
2.98
19.00%
Pharma Product
21.65
13.70
1.58
2.80%
1.92
20.48%
Activision
11.11
45.35
0.25
1.40%
1.24
20.63%
Video game makers Electronic Arts (ERTS) and Activision (ATVI) seemed to be in a race to the bottom until ATVI announced that its earnings beat expectations and that they are going to pay a dividend for the first time. On the news, ATVI moved higher while ERTS continues to languish within 9% of a new low. However, the fact that ERTS is so low and isn't promoting "positive" news makes the company more attractive.
Pharamceutical Product Development (PPDI) is again edging back on to our new low list. As you'll note on my 2009 transaction overview, PPDI was one of my most successful ventures from the Nasdaq 100 Watch List. Although not yet a Dividend Achiever, the company has increased the dividend every year for 4 years in a row. The company has solid financials and carries no debt.
Apollo Group (APOL) has remained on the Watch List for 4 months now. Provided that APOL doesn't fall below the November lows, this company may be worth investigating. With return on assets around 25% and return on equity at around 50% it would be difficult to ignore this special situation. However, my primary concern would be on the issues of long-term debt and quality of reported earnings.
As a group, Genzyme (GENZ), Stericycle (SRCL), Gilead (GILD), and PPDI are all companies that I would invest in, to varying degrees. The healthcare sector, as well as the water utilities on the Dividend Achiever Watch List are demonstrating their relative undervaluation against the overall market.

-Touc